Quick Answer
ORAMED PHARMACEUTICALS INC. reported Total Revenue of $2.00 million for fiscal year 2025.
ORAMED PHARMACEUTICALS INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.00M | — | $1.34M -50.4% |
$2.70M +0.0% |
$2.70M -0.3% |
$2.71M +0.3% |
| Net Income | $64.05M +436.0% |
-$19.06M -474.6% |
$5.09M +113.9% |
-$36.56M -59.0% |
-$22.99M -99.7% |
-$11.51M +19.8% |
| Diluted EPS | $1.50 +412.5% |
-$0.48 -442.9% |
$0.14 +114.9% |
-$0.94 | — | — |
| Total Assets | $230.86M +48.7% |
$155.28M -29.6% |
$220.55M +36.4% |
$161.64M +26.3% |
$128.00M +186.8% |
$44.63M +28.8% |
| Cash and Equivalents | $45.95M -15.6% |
$54.42M +501.0% |
$9.05M -77.6% |
$40.46M -47.6% |
$77.25M +300.3% |
$19.30M +479.6% |
| Stockholders Equity | $199.74M +36.6% |
$146.26M -10.7% |
$163.82M +7.9% |
$151.81M +31.1% |
$115.77M +252.1% |
$32.88M +69.5% |
| R&D Expense | $6.38M +0.9% |
$6.32M -29.5% |
$8.97M -67.5% |
$27.64M +31.7% |
$20.99M +105.1% |
$10.23M -24.3% |
| Operating Income | -$15.09M -18.1% |
-$12.78M +18.9% |
-$15.77M +61.2% |
-$40.60M -67.6% |
-$24.22M -106.0% |
-$11.76M +19.6% |
| Gross Profit | $13.0K | — | — | — | — | — |
| Shares Outstanding | 39.28M -1.6% |
39.92M -1.0% |
40.34M +2.0% |
39.56M +12.1% |
35.29M +49.1% |
23.68M +36.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2025 | $2.00M | — | +196.7% |
| Net Income | September 30, 2025 | $48.40M | +346.7% | +264.2% |
| Diluted EPS | September 30, 2025 | $1.13 | +335.4% | +264.5% |
| Total Assets | September 30, 2025 | $220.49M | +33.6% | +36.4% |
| Cash and Equivalents | September 30, 2025 | $52.18M | — | +230.3% |
| Stockholders Equity | September 30, 2025 | $203.28M | +29.9% | +31.5% |
| R&D Expense | September 30, 2025 | $1.15M | -48.6% | +11.5% |
| Operating Income | September 30, 2025 | -$2.43M | +21.4% | +2.5% |
| Gross Profit | March 31, 2025 | $13.0K | — | — |
| Shares Outstanding | September 30, 2025 | 40.84M | +1.6% | -0.0% |
- ORAMED PHARMACEUTICALS INC. reported Total Revenue of $2.00 million for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +49.3% in Total Revenue compared to the prior fiscal year.
- ORAMED PHARMACEUTICALS INC. reported Net Income of $64.05 million for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +436.0% in Net Income compared to the prior fiscal year.
- ORAMED PHARMACEUTICALS INC. reported Diluted EPS of $1.50 per share for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +412.5% in Diluted EPS compared to the prior fiscal year.
- ORAMED PHARMACEUTICALS INC. reported Total Assets of $230.86 million for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +48.7% in Total Assets compared to the prior fiscal year.
- ORAMED PHARMACEUTICALS INC. reported Cash and Equivalents of $45.95 million for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed a decrease of -15.6% in Cash and Equivalents compared to the prior fiscal year.
- ORAMED PHARMACEUTICALS INC. reported Stockholders Equity of $199.74 million for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +36.6% in Stockholders Equity compared to the prior fiscal year.
- ORAMED PHARMACEUTICALS INC. reported R&D Expense of $6.38 million for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +0.9% in R&D Expense compared to the prior fiscal year.
- ORAMED PHARMACEUTICALS INC. reported Operating Income of -$15.09 million for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed a decrease of -18.1% in Operating Income compared to the prior fiscal year.
- ORAMED PHARMACEUTICALS INC. reported Gross Profit of $13.0 thousand for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. reported Shares Outstanding of 39.28 million shares for fiscal year 2025.
- ORAMED PHARMACEUTICALS INC. showed a decrease of -1.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: